Full Text Full Text (PDF) Supplemental table Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via Google Scholar Articles by Guo, J. J. Articles by Patel, N. C. Search for Related Content PubMed Citation Articles by Guo, J. J. Articles by Patel, N. C. Costs, Cost Analysis Health Insurance Bipolar Disorder Atypical Neuroleptics Conventional Neuroleptics Related Article

Treatment Costs Related to Bipolar Disorder and Comorbid Conditions Among Medicaid Patients With Bipolar Disorder

OBJECTIVE: This study assessed costs among patients with bipolar disorder for treatment related to bipolar disorder and to comorbid conditions. Risk factors associated with costs were also assessed. METHODS: Data (January 1998 to December 2002) were from a seven-state Medicaid managed care claims database for 13,471 patients who had received a diagnosis of bipolar disorder, most of whom received medications. Each medical claims cost was adjusted by the medical component of the Consumer Price Index as the dollar value in 2002. In a Poisson regression analysis, treatment costs per enrollment month were regressed on patient's age, gender, medications, and clinical comorbidities. RESULTS: Bipolar disorder treatment accounted for 30% of costs and comorbid disorders for 70%. Key cost components were inpatient care (35%), outpatient care (16%), prescriptions (13%), and physician encounters (11%). Patients with bipolar disorder received a variety of medications: lithium, 13%; anticonvulsants, 35%; second-generation antipsychotics, 24%; first-generation antipsychotics, 22%; and antidepressants, 42%. Compared with the costs for patients receiving antidepressants alone or no medication, the high costs for bipolar disorder treatment and overall treatment were associated with use of second-generation antipsychotics (rate ratio [RR]=1.71, 95% confidence interval [CI]=1.58–1.86 and RR=1.26, CI=1.18–1.34, respectively) and use of anticonvulsants (RR=1.37, CI=1.26–1.48 and RR=1.06, CI=1.00–1.12). Higher costs were significantly associated with key comorbidities, such as drug abuse (RR=1.58, CI=1.47–1.70), cerebral-vascular disease (RR=1.72, CI=1.51–1.94), ischemic heart disease (RR=1.47, CI=1.30–1.66), and hypertension (RR=1.44, CI=1.33–1.56). CONCLUSIONS: Cost-containment efforts may need to manage or prevent key comorbidities among patients with bipolar disorder and to evaluate the association between antipsychotic use and treatment outcomes and hospital services.

Related Article:

August 2007: This Month's Highlights
Psychiatr Serv 2007 58: 1031. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2007 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us